Bailard, Inc. Athira Pharma, Inc. Transaction History

Bailard, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 08, 2024	BUY	$2.24 - $4.15 $90,659 - $167,962	40,473 New	40,473 $110,000
Q1 2023 May 08, 2023	SELL	$2.26 - $4.22 $25,311 - $47,264	-11,200 Reduced 24.84%	33,894 $84,000
Q4 2022 Feb 02, 2023	BUY	$2.76 - $3.71 $124,459 - $167,298	45,094 New	45,094 $142,000

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $20.4M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

Stay updated on Bailard, Inc. with notifications on news.